Biotron Limited · ASX:BIT
Biotron — Investor Presentation (February 2007)
20 slides from Biotron's investor presentation, Feb 8, 2007
Slide 1: Presentation of Company Activities
BIOTEC OT timitea A.BN, 60 086 399 144 Level 8, 261 George Street Sydney NSW 2000 Tel: (61-2) 9247 8212 Fax: (61-2) 9247 3932 E-mail: pnightingale@biotron.com.au Website: www.biotron.com.au 8 February 2007 The Manager Companies Australian Stock Exchange Limited 20 Bridge Street Sydney NSW 2000 (20 p
Slide 2: Biotron - Dr. Michelle Miller, February 2007
Biotrtron Dr. Michelle Miller February 2007
Slide 3: sos
— sos 2 — — . C#” Cl ON: ep ae = 7) 7 L
Slide 4: Products: Biotron's Project Pipeline by Stage of Development
__ PRODUCTS Biotron’s Project Pipeline by Stage of Development
Slide 5: Ly ye a
Ly ye a 7 LE y uy UE ) y oe, 7 ee La SO i Lg. oo : Lo Ls Ly, _ a ce _ Oe is - ITI To TS nen ee a Ge Ls ie ye 7 _ / Le Us Ye a y : / : ey y i 7 Cc Oe s LS ie co & 26 oe — eS De Ce Le 7 a
Slide 6: Des y We iy ee
Des y We iy ee i a i _ — We EI 7 Te 7 y ; Lo g Ly a TT 7 Lo . SC y 7 Q i J yy 7 Lo Do . | a De Ly: . y CD DCU y a Le
Slide 7: BIT compounds interrupt budding
Assembly & bugding Penetration gpi20 BIT compounds interrupt budding Attachment
Slide 8: Current HIV drugs cannot eradicate the underlying seat of infection
- Current HLV drugs cannot eradicate the underlying seat of infection (termed the viral reservoir) Measurement of HIV Production by Infectivity of Virus Produced Solvent Control BIT 225 (20uM) BIT 225 (20uM) new old
Slide 9: BIT225 inhibits HIV-1 associated pathology
BIT225 INHIBITS HIV-1 ASSOCIATED = = SEPATHOLOGY sisi‘ T-cells co-cultured with HIV-infected macrophages, NB High pathology associated with controls ine. ceil ballooning and apgpregation
Slide 10: nee
a _ — Ee ee nee oe oo TesenE Oe —
Slide 11: pera
pera oT 7 oe ~ : weer 3 a ee, Le — y y oe ae - DO) ae y EN le ; Ly My ue ey — Lo Ve = o Ls heart Ve dee a y oy Lr Le, ey Le Lo yo Lo, 7 oy LLL J _ eae Be i Cy ee oe KG Ge e sie ge Oe ; Co 7 e Yi SS = SS Ty ay ay 7 y
Slide 12: Comprehensive preclinical program supports progression to human trials
SS — oe ee oe — > Comprehens cal plet ingm Ive program suppor Ss ion of th ts progression to human tual i in cl 1 oO = x = Pa © “4 wm ot c Le) Da oO (as [or o [asi oO D a eS is p ilestone for BIT . : Com add
Slide 13: AN OTA
— o a) AN OTA Dice
Slide 14: chaos —
| chaos — a - t. — — — oo to 1c . ineffective and tox ly o 2 . lat 1€S8 te therapi ing t . 1S * Ex
Slide 15: Ee oo oo
2 ee 7 Ee oo oo Ue a 4g i i Ly ey ; ae DO Vay) oe Z 7 ae 7 i fe _ Le a ee yy | , ; 7 Lo y LD, ae eon yey ee a Lo
Slide 16: Milestone payments - Boehringer Ingelheim
So -— — = — — 0 ilestone Im up to US$470m m Ingelhe 5 inger a eo & A 5 ta and Boehr $103m US$60m up ch phase ical; Bio — Preclini payments °06 — Resear Nov —
Slide 17: Q ee ae Lee oy Ls
a 7 a Q ee ae Lee oy Ls Lo Lo 8 Lo i oo : : 2 y Ly ce Vig a Le A 2 a Z woe uy y ED IH re es He Bae y ee > Ce ay Ly, Lo oy 7 We OU: LLL EEE AEE LE: SG: Cy Loe i ey) ie De oe Lie oo 7 a Ly Ly
Slide 18: a a — ao yy a ee ] y a yy a lo i:
a a — ao yy a ee ] y a yy a lo i: i ee LI joe ay Lo Lo a ee 7 ys Ly Lo 7 a, ee ne Ye 7 oy _ a 7 ) ey a Ls y CU y Le oe ee He y Ly e De Le oa)
Slide 19: ee y ae ye oe oe
yo ee y ae ye oe oe Wye zy ey ee, 7 Ly i 7) ee d eB Ae ay ayy DISS IESE ae oy Ce Y XN Oe UE WS a Lo | ] ] - oe Le oe a Co. a Le Le ce ay A vy se ey yo ; LL Me oo 7 Lee sie le eS Es Lise : ie ter ee SS 4 hi Case We Ss a es e Bs cede ae nen
Slide 20: Dr Michelle Miller
Dr Michelle Miller Chief Executive Officer 02 6125 8001 mmiller@biotron.com.au www.biotron.com.au